Previous Article | Next Article 
Infection and Immunity, October 1999, p. 5282-5291, Vol. 67, No. 10
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cryptosporidium parvum Apical Complex Glycoprotein CSL
Contains a Sporozoite Ligand for Intestinal Epithelial
Cells
Rebecca C.
Langer
and
Michael W.
Riggs*
Department of Veterinary Science and
Microbiology, University of Arizona, Tucson, Arizona 85721
Received 10 May 1999/Returned for modification 14 June
1999/Accepted 2 July 1999
 |
ABSTRACT |
Cryptosporidiosis, caused by the apicomplexan parasite
Cryptosporidium parvum, has become a well-recognized
diarrheal disease of humans and other mammals throughout the world. No
approved parasite-specific drugs, vaccines, or immunotherapies for
control of the disease are currently available, although passive
immunization with C. parvum-specific antibodies has some
efficacy in immunocompromised and neonatal hosts. We previously
reported that CSL, an ~1,300-kDa conserved apical
glycoprotein of C. parvum sporozoites and
merozoites, is the antigenic species mechanistically bound by
neutralizing monoclonal antibody 3E2 which elicits the circumsporozoite
precipitate (CSP)-like reaction and passively protects against C. parvum infection in vivo. These findings indicated that CSL has a
functional role in sporozoite infectivity. Here we report that CSL has
properties consistent with being a sporozoite ligand for intestinal
epithelial cells. For these studies, native CSL was isolated from whole
sporozoites by isoelectric focusing (IEF) following observations that
the ~1,300-kDa region containing CSL as seen by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis was comprised of
approximately 15 molecular species (pI 3 to 10) when examined by
two-dimensional (2-D) electrophoresis and silver staining. A subset of
six ~1,300-kDa species (pI 4.0 to 6.5) was specifically recognized by
3E2 in 2-D Western immunoblots of IEF-isolated CSL. Isolated native CSL
bound specifically and with high affinity to permissive human
intestinal epithelial Caco-2 cells in a dose-dependent, saturable, and
self-displaceable manner. Further, CSL specifically bound to the
surface of live Caco-2 cells inhibited sporozoite attachment and
invasion. In addition, sporozoites having released CSL after incubation
with 3E2 and occurrence of the CSP-like reaction did not attach to and
invade Caco-2 cells. These findings indicate that CSL contains a
sporozoite ligand which facilitates attachment to and invasion of
Caco-2 cells and, further, that ligand function may be disrupted by
CSL-reactive monoclonal antibody. We conclude that CSL is a rational
target for passive or active immunization against cryptosporidiosis.
 |
INTRODUCTION |
Cryptosporidium parvum is
an apicomplexan parasite that commonly causes diarrhea in humans,
calves, and other economically important food animals throughout the
world (14). The infection is transmitted by fecal, food, and
waterborne routes and is initiated when sporozoites released from
oocysts in the intestinal tract attach to and invade mucosal epithelial
cells (14). Although progress has been made, control of
cryptosporidiosis remains problematic due to the absence of approved
vaccines or immunotherapies and lack of consistently effective
parasite-specific pharmaceuticals (3, 35). Because apical
complex and surface molecules of the apicomplexa are involved in
attachment, invasion, and intracellular development, these molecules
may provide targets for immunological or pharmacological therapy
against cryptosporidiosis (4, 7, 12, 25, 43, 50). To this
end, we recently reported the production and characterization of a
panel of mouse monoclonal antibodies (MAbs) against multiple epitopes
of immunoaffinity-purified apical complex and surface antigens of
C. parvum sporozoites (40). The ability of these
MAbs to neutralize C. parvum infectivity and thereby
identify parasite molecules involved in the pathogenesis of infection
was determined (22, 40). One of the MAbs, designated 3E2,
was central in these studies because of its ability to elicit distinctive morphologic changes in both sporozoites and merozoites, neutralize their infectivity in vitro, and control infection in vivo
(40). The structural and functional consequences of zoite exposure to MAb 3E2 (40) closely paralleled the
neutralization-associated circumsporozoite precipitate (CSP) reaction,
originally described for Plasmodium spp. sporozoites after
incubation with antibody against the circumsporozoite protein, an
apical-complex-derived sporozoite exoantigen (10, 30).
The CSP reaction is hypothesized to mimic a process normally initiated
by sporozoite attachment to host cell receptors during infection and
result in premature shedding of attachment and invasion molecules on,
or translocated to, the sporozoite surface (30). MAb 3E2
recognizes multiple sporozoite glycoproteins of 46 to 230 kDa, ~770 kDa, and ~1,300 kDa in Western blots (40). The
~1,300-kDa glycoprotein, an apical exoantigen designated
CSL, is the antigen species mechanistically targeted by MAb 3E2 and
hyperimmune bovine colostral antibody in the CSP-like reaction of
C. parvum (36, 40). CSL is conserved on
geographically diverse C. parvum isolates and expresses a
repetitive carbohydrate-dependent epitope recognized by MAb 3E2
(40). The sporozoite neutralizing activity of MAb 3E2 in
vitro and its ability to control infection in vivo are profoundly
greater than that of 116 additional MAbs produced in our laboratory
against distinct epitopes of other neutralization-sensitive C. parvum antigens, including CPS-500 (22, 37, 38),
GP25-200 (22, 35, 36, 40), and P23 (22, 32, 35).
Collectively, these observations provided the rationale for the present
study to further characterize the function of CSL in the pathogenesis
of infection and the mechanism by which MAb 3E2 neutralizes
infectivity. Because region II-plus of the circumsporozoite protein
target of the CSP reaction in Plasmodium spp. has been shown
to contain a sporozoite ligand for host cell receptors (8, 9,
33), we hypothesized that CSL functions as a sporozoite ligand
for epithelial cells in the initiation of C. parvum
infection. Indeed, the high efficiency of C. parvum
infection indicated by low infective doses (14) and the
rapidity with which C. parvum sporozoites locate, attach to,
and invade epithelial cells after excystation suggest a ligand-receptor relationship (14, 25, 35). We further hypothesized that MAbs
against CSL which elicit the CSP-like reaction inhibit infection of
epithelial cells by preventing sporozoite attachment and/or invasion.
Here we report that CSL binds specifically and with high affinity to
the surface of viable Caco-2 intestinal epithelial cells and, once
bound, significantly diminishes their permissiveness to infection by
C. parvum sporozoites. Further, after binding of MAb 3E2 to
sporozoites and occurrence of the CSP-like reaction with accompanying
release of CSL, the attachment of sporozoites to Caco-2 cells is
inhibited. Finally, we demonstrate that CSL, which previous studies
suggested was a single glycoprotein (40), is
comprised of multiple ~1,300-kDa molecular species with differing isoelectric points (pI). We conclude that CSL functions as a sporozoite ligand, facilitating the attachment to and invasion of intestinal epithelial cells.
(Some of the research findings contained here were presented in part as
a preliminary report at the Fourth International Workshops on
Opportunistic Protists on 13 June 1996 in Tucson, Ariz.
[23]).
 |
MATERIALS AND METHODS |
Oocyst and sporozoite isolation.
The Iowa C. parvum isolate (19) used in all experiments was
propagated in newborn Cryptosporidium-free Holstein bull
calves to obtain parasite material for study (39). Oocysts
were isolated by sucrose density gradient centrifugation and stored in
2.5% (wt/vol) KCr2O7 (4°C) prior to use
(1). Immediately prior to excystation, oocysts were treated
with hypochlorite (39). Sporozoites were isolated from
excysted oocyst preparations by passage through a polycarbonate filter
(2.0 µm, pore size; Poretics, Livermore, Calif.).
Isolation of CSL and control glycoproteins CPC205 and
Tf190.
CSL was isolated from whole C. parvum by
isoelectric focusing (IEF) as follows. Excysted oocysts were
solubilized in lysis buffer [50 mM Tris (pH 8.0), 5 mM
4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), 0.3 µM aprotinin,
10 µM E-64, 0.01 mM leupeptin, 5 mM EDTA, 130 µM bestatin, and 1%
(wt/vol) octyl-glucoside]. Parasite molecules in the soluble fraction
were then separated by preparative IEF (12 W, 4 h, 4°C)
according to the manufacturer's protocol (Rotofor; Bio-Rad, Hercules,
Calif.), enriching for those of pI 3.5 to 5.0. CSL-containing fractions
were identified by dot immunoblot by using MAb 3E2 (immunoglobulin M
[IgM] isotype) as previously described (40) and then
combined and concentrated by centrifugation (10,000 × g, 4°C; Centriprep 30; Amicon, Beverly, Mass.). The purity of
isolated CSL was determined by silver staining the preparation resolved
by 10 to 20% and 2 to 12% gradient sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) reducing gels
(40). Immunoreactivity and identity of isolated CSL were
determined by Western blotting the preparation resolved in 10 to 20%
and 2 to 12% gradient SDS-PAGE reducing gels (40). Blots
were probed with MAb 3E2 or isotype-matched control MAb of irrelevant
specificity (each at 8 µg/ml), and bound MAb was detected with
affinity-purified phosphatase-conjugated goat anti-mouse IgM (Zymed,
San Francisco, Calif.) and phosphatase substrate. MAbs used in these
and all experiments described below were derived from hybridoma culture supernatant.
Two additional glycoproteins, CPC205 and Tf190, were
isolated for use as negative controls in experiments to assess the
binding specificity of CSL to Caco-2 cells (described below). CPC205, a
205-kDa C. parvum oocyst wall glycoprotein, is
defined by mouse MAb 4D3 (IgM isotype). MAb 4D3 was prepared against
immunoaffinity chromatography-isolated GP25-200 as previously described
(40), binds to oocyst shells but not sporozoites or
merozoites in immunofluorescence assays (IFA), and recognizes a
carbohydrate-dependent epitope on multiple oocyst shell
glycoproteins of >40 kDa in Western blots. CPC205 was
isolated from oocyst shells by continuous elution gel electrophoresis
according to the manufacturer's protocol (Bio-Rad) as follows. Oocysts
(5 × 108) were excysted, layered onto a Percoll
(Pharmacia, Alameda, Calif.) gradient (Percoll [nine parts], 10×
Alsever's solution [one part], 1× Alsever's solution [nine
parts]), and centrifuged (40,000 × g, 30 min, 4°C).
Gradient fractions (1 ml) were examined by phase-contrast microscopy,
and those containing excysted oocyst shells, but not intact oocysts or
sporozoites, were pooled and washed four times (16,000 × g, 10 min, 4°C) with phosphate-buffered saline (PBS; pH 7.4)
containing protease inhibitors (5 mM AEBSF, 0.3 µM aprotinin, 10 µM
E-64, 0.01 mM leupeptin, 5 mM EDTA, and 130 µM bestatin). Oocyst
shells were then resuspended in reducing SDS-PAGE sample buffer (0.06 M
Tris HCl [pH 6.8], 2% [wt/vol] SDS, 5% [vol/vol]
-mercaptoethanol, 10% [vol/vol] glycerol, 0.025% [wt/vol]
bromophenol blue), boiled (4 min), centrifuged (20,000 × g, 10 min, 4°C) to remove insoluble material, and resolved in an
SDS-4% PAGE gel by using a Prep Cell (Bio-Rad) for fractionation.
Samples from eluted fractions were resolved in 2 to 12% gradient
SDS-PAGE reducing gels and silver stained to identify those containing
a 205-kDa band corresponding to CPC205 and to determine purity.
Immunoreactivity and identity of isolated CPC205 were determined by
Western blotting of silver stain-positive fractions resolved in 2 to
12% gradient SDS-PAGE reducing gels. Blots were probed with MAb 4D3 or
isotype-matched control MAb (each at 8 µg/ml), and bound MAb was
detected with affinity-purified phosphatase-conjugated goat anti-mouse
IgM (Zymed) and phosphatase substrate. Tf190, the second negative
control glycoprotein, is an adhesion molecule of
Tritrichomonas foetus defined by mouse MAb 32.3B3.5 (IgG1
isotype) (5, 46). MAb 32.3B3.5 recognizes a
carbohydrate-dependent epitope on an ~190-kDa surface-exposed
glycoprotein complex in Western blots (5). Tf190
was isolated from whole T. foetus by preparative
electrophoresis as follows. The KV-1 isolate of T. foetus
was cultured in Diamond's medium (48 h, 37°C) (11),
centrifuged (15,000 × g, 10 min, 4°C), resuspended
in lysis buffer, disrupted by sonication (4°C), and ultracentrifuged
(50,000 × g, 30 min, 4°C) to remove insoluble material. The soluble fraction was diluted with non-reducing sample buffer, boiled (4 min), and resolved in an SDS-7.5%-PAGE gel under nonreducing conditions. A gel strip spanning the 180- to 200-kDa region
containing Tf190 was excised and electroeluted according to the
manufacturer's protocol (Six-Pack gel eluter; Hoeffer Scientific, San
Francisco, Calif.). Purity of isolated Tf190 was determined by silver
staining the electroeluted preparation resolved in an SDS-7.5%-PAGE
nonreducing gel. Immunoreactivity and identity of isolated Tf190 were
determined by Western blotting of the preparation resolved in an
SDS-7.5%-PAGE nonreducing gel. Blots were probed with MAb 32.3B3.5 or
isotype-matched control mAb (each at 1 µg/ml), and bound MAb was
detected with affinity-purified alkaline phosphatase-conjugated goat
anti-mouse IgG1 (Zymed) and phosphatase substrate.
To determine if the biologically relevant CSL species bound by MAb 3E2
during the CSP-like reaction had been isolated by the
IEF method
described above, the ability of isolated CSL to competitively
inhibit
the reaction was evaluated as follows. Viable, purified
sporozoites
(1.2 × 10
5 in 10 µl PBS) were coincubated (30 min,
37°C) with MAb 3E2 (0.5
µg) and IEF-isolated CSL (2.5 µg) and
then observed by phase-contrast
microscopy to determine the percentage
of sporozoites undergoing
the CSP-like reaction ([number of
sporozoites undergoing CSP-like
reaction

total number of
sporozoites counted] × 100). A total
of 200 sporozoites was counted
in each of two replicate experiments.
In parallel, the percentage of
sporozoites undergoing the CSP-like
reaction was determined in control
preparations incubated under
identical conditions with (i) MAb 3E2 (0.5 µg), (ii) isotype-matched
control MAb of irrelevant specificity (0.5 µg), (iii) MAb 3E2
(0.5 µg) and isolated CPC205 (2.5 µg), (iv)
MAb 3E2 (0.5 µg) and
isolated Tf190 (2.5 µg); or (v) MAb 3E2 (0.5 µg) and the soluble
fraction from
C. parvum sporozoites
(2.5 µg). For the latter control,
sporozoites were disrupted by
freeze-thawing and sonication (4°C)
in lysis buffer and then
ultracentrifuged to remove insoluble
material and dialyzed (12- to
14-kDa exclusion limit) against
PBS (4°C) prior to use. The
glycoprotein concentration in CSL,
CPC205, Tf190, and
solubilized sporozoite samples was determined
by the microbicinchoninic
acid method (Pierce, Rockford, Ill.)
with bovine
glycoprotein purified from Cohn fraction VI (G9014;
Sigma,
St. Louis, Mo.) as a standard. Percent CSP-like reaction
values for
test and control preparations were examined for significant
differences
by using the Student's one-tailed
t test.
2-D electrophoretic analysis of whole C. parvum and
isolated CSL.
The glycoprotein species composition of
IEF-isolated CSL was analyzed by two-dimensional (2-D) electrophoresis
(2-D Electrophoresis Cell; Bio-Rad) and compared to that of whole
C. parvum by using a previously described method with some
modifications (29). For whole C. parvum analysis,
excysted oocysts were boiled (3 min) in 2-D sample buffer (0.06 M Tris
[pH 6.8], 5% [wt/vol] SDS, 5% [vol/vol]
-mercaptoethanol,
10% [vol/vol] glycerol), sonicated (4°C), and subjected to
freeze-thawing, after which the insoluble fraction was removed by
ultracentrifugation. CSL was isolated by preparative IEF as described
above, solubilized in 2-D sample buffer, and ultracentrifuged to remove
insoluble material prior to analysis. First-dimension tube gels (9.2 M
urea, 4% [wt/vol] acrylamide, 20% [vol/vol] Triton X-100, 1.6%
[vol/vol] Biolyte 5/7, 0.4% [vol/vol] Biolyte 3/10, 0.01%
[wt/vol] ammonium persulfate, 0.1% [vol/vol] TEMED
[N,N,N',N'-tetramethylethylenediamine])
were cast in 1 mm (inner diameter) glass capillary tubes, loaded with the soluble fraction from excysted oocysts or isolated CSL, and subjected to IEF (6 h, 750 V). After IEF, tube gels were laid onto 2 to
12% gradient SDS-PAGE reducing gels and resolved in the second
dimension (200 V, 1 h). Second-dimension gels were then silver
stained to identify the ~1,300-kDa (i.e., 1,200 to 1,400 kDa)
(glyco)protein species in whole C. parvum (3 × 107 excysted oocysts) or isolated CSL (10 µg). To
characterize the ~1,300-kDa species specifically recognized by MAb
3E2, second-dimension gels containing isolated CSL (6 µg) were
electrotransferred (100 V, 1 h; Trans-Blot Cell; BioRad) to
polyvinylidene difluoride membranes for Western blotting. Briefly, the
membranes were incubated (1 h, 21°C) with MAb 3E2 or isotype-matched
control MAb (each at 1 µg/ml), washed 12 times with buffer B
(36) containing 5% (wt/vol) nonfat dry milk, incubated (1 h, 21°C) with affinity-purified alkaline phosphatase-conjugated goat
anti-mouse IgM (Zymed), washed four times with buffer B containing 5%
(wt/vol) nonfat dry milk, washed four times with buffer B, washed two
times with 0.1 M Tris (pH 9.0), and then developed with
chemiluminescence substrate (Bio-Rad) and photographed. The same
membranes were then stripped of antibodies (0.1M Tris [pH 6.7], 20%
[wt/vol] SDS, 0.7% [vol/vol]
-mercaptoethanol; 12 h,
21°C) as previously described (17) and reprobed
identically with mouse MAb 4D10 (IgM isotype). MAb 4D10 binds to an
~1,300-kDa glycoprotein in Western blots of whole C. parvum or IEF-isolated CSL but, unlike MAb 3E2,
recognizes a peptide epitope and does not elicit the CSP-like reaction
(40). Therefore, it was of interest to compare the
reactivity patterns of MAbs 3E2 and 4D10 with IEF-isolated CSL in 2-D
Western blots.
Effect of MAb 3E2 on sporozoite attachment and invasion.
To
quantitate specific neutralizing activity of MAb 3E2 against the
infective sporozoite stage, an in vitro neutralization assay was
performed. Purified sporozoites (1.2 × 105 in 200 µl of minimum essential medium [MEM]) were incubated (15 min,
37°C, 10% CO2) with MAb 3E2 or isotype-matched control
MAb (10 µg/ml each) and then inoculated onto individual Caco-2 cell monolayer cultures (three replicates per treatment). Monolayers had
been grown to ~90% confluency on glass coverslips (12 mm in diameter) in complete MEM (MEM containing 10% fetal bovine serum, 1%
nonessential amino acids, 100 U of penicillin per ml, and 100 µg of
streptomycin per ml) prior to inoculation. At 24 h postinoculation (p.i.), coverslip cultures were washed with PBS, methanol fixed (30 s),
blocked (PBS containing 3.2% [wt/vol] fish gelatin and 2%
[wt/vol] bovine serum albumin [BSA]), and processed for IFA by
using MAb 4B10 and affinity-purified fluoresceinated goat anti-mouse IgG-IgM-IgA (Kirkegaard & Perry, Gaithersburg, Md.) to detect intracellular stages. MAb 4B10, prepared against immunoaffinity chromatography-isolated GP25-200 as previously described
(40), recognizes C. parvum stages in Caco-2 cells
through 72 h p.i. (22, 23). Each coverslip culture was
systematically examined in its entirety by the same investigator by
epifluorescence microscopy to directly quantitate the number of
intracellular stages per monolayer. The mean numbers of intracellular
stages in test and control cultures were examined for significant
differences by using Student's one-tailed t test. After
quantitation of MAb 3E2-mediated sporozoite neutralization, specific
effects of the MAb on attachment and invasion events of the infection
process were examined. Purified sporozoites (6 × 104
in 30 µl of MEM) were incubated (15 min, 37°C, 10%
CO2) with MAb 3E2 or isotype-matched control MAb (final
concentration, 15 µg/ml each) and then inoculated onto individual
Caco-2 cell monolayers immediately after aspiration of the culture
medium. Monolayers had been grown in complete MEM to ~90% confluency
in eight-well-chamber coverglass slides (Nalge Nunc International,
Naperville, Ill.) prior to inoculation. Interaction of MAb-treated
sporozoites with Caco-2 cells was observed with a Nomarski differential
interference contrast inverted microscope (Ziess) and recorded by video
photomicroscopy (Cohu, San Diego, Calif.). In each of eight replicate
experiments, 15 MAb 3E2- or control mAb-treated sporozoites were
observed over a 30-min period by the same investigator.
Effect of CSL incubation with Caco-2 cells on sporozoite
attachment and invasion.
To determine if CSL could bind
specifically to Caco-2 cells, an in vitro binding assay was performed
as follows. After dialysis (exclusion limit of 12 to 14 kDa) against
PBS (4°C) and ultracentrifugation (50,000 × g, 30 min, 4°C) to remove insoluble material, 2 µg each of isolated CSL,
CPC205, or Tf190 was incubated (15 min, 21°C) with viable Caco-2 cell
monolayers grown to ~90% confluency on coverslips as described above
(three replicates per treatment). Coverslip cultures were then washed
six times with PBS and processed for IFA as described above. The
binding specificity was assessed by epifluorescence microscopy with MAb
3E2 for cultures incubated with CSL, MAb 4D3 for cultures incubated
with CPC205, or MAb 32.3B3.5 for cultures incubated with Tf190. In
parallel, replicates of each culture preparation were processed
identically by using isotype-matched control MAbs of irrelevant
specificity. Observations were validated in three separate replicate experiments.
To determine whether incubation of Caco-2 cells with CSL would affect
their permissiveness to sporozoite attachment and/or
invasion,
coverslip cultures were incubated as described above
with increasing
quantities (0.25 to 2.0 µg/monolayer) of isolated
CSL, CPC205, or
Tf190 (three replicates per treatment). Cultures
were then inoculated
with purified sporozoites (1.2 × 10
5/monolayer),
incubated (24 h, 37°C, 10% CO
2), washed with PBS,
and
processed for epifluorescence microscopy as described above
with MAb
7B6 to quantitate intracellular stages. MAb 7B6 recognizes
C. parvum stages in Caco-2 cells through 72 h p.i., binds to
multiple
58- to 200-kDa sporozoite glycoproteins in Western
blots, and
is unreactive with CSL (
22,
23). MAb 7B6 was used
in these
experiments to facilitate accurate identification and
quantitation
of intracellular stages because it was observed in the in
vitro
binding assay described above that MAbs 3E2 and 4B10 detected
CSL
specifically bound to Caco-2 cells. Cell viability was determined
in
parallel monolayer cultures after incubation with CSL, CPC205,
or
Tf190. For each preparation, a minimum of 200 cells was observed
by
epifluorescence microscopy by using an acridine orange and
ethidium
bromide viability assay (
13).
Characterization of binding kinetics of CSL to Caco-2 cells.
For use in binding kinetics studies, CSL was radioiodinated by the
Iodobead method (Pierce). Briefly, Iodobeads, IEF-isolated CSL (100 µg in 1 ml of PBS), and 125I-labeled Na (0.5 mCi)
(Dupont-NEN, Wilmington, Del.) were incubated (30 min, 4°C) with
rocking, after which KI (0.5 mM) and protease inhibitors were added,
and the supernatant was collected. The solution containing
125I-CSL was then dialyzed (exclusion limit of 12 to 14 kDa) against PBS (4°C). Trichloroacetic acid (TCA)-precipitable
incorporation of 125I was approximately 4,240 cpm/µg of
CSL (18). To determine if radioiodination affected CSL
binding to Caco-2 cells, 125I-CSL or unlabelled CSL was
incubated (30 min, 4°C) with viable Caco-2 cells (4 µg of
CSL/monolayer), which were then processed for IFA as described above
with MAb 3E2 or isotype-matched control MAb to detect bound CSL. The
specific immunofluorescence pattern and intensity with MAb 3E2 were
indistinguishable in Caco-2 cell monolayers which had been incubated
with either unlabeled CSL or 125I-CSL.
For all binding kinetics experiments, Caco-2 cells were cultured in
complete MEM in 96-well plates to ~90% confluency prior
to use. To
construct a binding curve, monolayers were incubated
(30 min, 4°C) in
quadruplicate with increasing quantities of
125I-CSL (0.06, 0.13, 0.25, 0.50, 1.0, 2.0, or 4.0 µg/monolayer).
Unlabeled CSL (0.25 µg/monolayer) was included with
125I-CSL (1.0, 2.0, and
4.0 µg) to level the binding curve in the
upper half of the titration
(
6,
44). After incubation, cells
were transferred to
microfuge tubes, centrifuged (4,000 ×
g, 10
min,
4°C) to remove incubation medium, and washed three times
with PBS
(4°C). Cells were then resuspended in PBS (100 µl/monolayer),
placed in scintillation vials, and bound
125I-CSL (in
counts per minute) was determined for each treatment
group with a gamma
counter. Nonspecific
125I-CSL binding was determined by
incubating (30 min, 4°C) monolayers
in quadruplicate with an amount
of unlabelled CSL (7.0 µg/monolayer)
exceeding that required for
saturation of binding sites, as determined
from the preceding
experiment and saturability experiments described
below, and repeating
the titration with
125I-CSL (0.06 to 4.0 µg/monolayer).
These data were used to correct
the binding curve for nonspecific
binding (
6,
24,
44).
To determine if CSL binding was
self-displaceable, monolayers
were incubated (30 min, 4°C) in
quadruplicate with a fixed quantity
of
125I-CSL (0.25 µg/monolayer) and increasing quantities of unlabeled
CSL (0.06, 0.13, 0.25, 0.50, 1.0, 2.0, or 4.0 µg/monolayer) (
6,
24). After
incubation, cells were washed with PBS, and bound
counts per minute
were determined. To determine if CSL binding
was saturable, monolayers
were incubated (30 min, 4°C) in quadruplicate
with increasing
quantities of
125I-CSL (0.06, 0.13, 0.25, 0.50, 1.0, 2.0, or 4.0 µg/monolayer).
After incubation, the medium was collected, and
the cells were
washed with PBS, after which cell-bound and free counts
per minute
were determined. Bound-to-free ratios of
125I-CSL (in counts per minute) were then plotted against
the corresponding
quantity of
125I-CSL (in micrograms)
incubated with each culture. A Scatchard
plot was constructed by using
B/F ratios and the corresponding
125I-CSL counts per minute
bound by each culture (
24). To calculate
specific activity
of the
125I-CSL used in binding saturability experiments
and Scatchard plot
construction, the maximal binding capacity of
125I-CSL was determined (
6,
44). In brief,
increasing numbers
of Caco-2 cells (10
5, 2 × 10
5, 3 × 10
5, 4 × 10
5,
or 5 × 10
5) were incubated (30 min, 4°C) in
triplicate with a fixed quantity
of
125I-CSL (0.25 µg/cell preparation). Cells were then PBS washed,
and the amounts of
bound counts per minute were determined. All
data from binding kinetics
experiments were analyzed by nonlinear
least-squares fit by using the
program LIGAND to calculate the
association (
KA)
and dissociation (
KD) constants (
28).
 |
RESULTS |
Isolation of CSL, CPC205, and Tf190.
IEF-isolated CSL
comigrated with an ~1,300-kDa band in solubilized whole
C. parvum and was relatively free of contaminating lower Mr (glyco)proteins as determined by
SDS-PAGE and silver staining (Fig. 1A).
In Western blots, isolated CSL was specifically recognized by MAb 3E2,
comigrated with an ~1,300-kDa antigen recognized in whole C. parvum, and was free of lower Mr antigens
(Fig. 1B). These data confirmed the utility of IEF for isolation of
native CSL from whole C. parvum.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Silver-stained 2 to 12% gradient SDS-PAGE gel of
solubilized oocysts before (lane 1, 105) and after (lane 2, 1.4 µg) IEF isolation of CSL (arrow). Lane 3 was loaded with sample
buffer to identify silver-stain artifacts. (B) Western blot recognition
of IEF-isolated CSL (lane 2, 0.5 µg) (arrow) and an ~1,300-kDa
comigrating antigen in solubilized oocysts (lane 1, 7 × 106) by MAb 3E2. Lane 3 (7 × 106
solubilized oocysts) and lane 4 (0.5 µg of CSL) were probed with
isotype control MAb. Molecular mass standards are indicated on the left
(titin, 2,450 kDa, and nebulin, 770 kDa [obtained from Kuan Wang and
Gustavo Gutierrez, University of Texas, Austin]; myosin, 208 kDa;
-galactosidase, 144 kDa; and BSA, 87 kDa [Bio-Rad]).
|
|
Because CPC205 is oocyst wall-specific and is not expressed by the
infective sporozoite or merozoite stages, it was considered
an
appropriate
C. parvum-derived control
glycoprotein having no
known biologic role in the infection
process. Because Tf190 functions
in adhesion of
T. foetus to
epithelial cells, it was considered
an appropriate
C. parvum-related protozoan control glycoprotein
having a
known biologic role in the pathogenesis of infection.
In silver-stained
SDS-PAGE gels, electrophoretically isolated
CPC205 (Fig.
2A) and Tf190 (Fig.
2C) comigrated with
bands of
corresponding
Mr in the whole-organism
preparations from which
they were derived and were relatively free of
contaminating (glyco)proteins.
Similarly, in Western blots, isolated
CPC205 (Fig.
2B) and Tf190
(Fig.
2D) were specifically recognized by
MAbs 4D3 and 32.3B3.5,
respectively, and comigrated with antigens of
corresponding
Mr recognized in whole organism
preparations. Isolated CPC205 was
free of the higher and lower
Mr antigens recognized by MAb 4D3
in whole
C. parvum (Fig.
2B) and was unreactive with MAb 3E2 in
Western blots. A 160-kDa antigen in the Tf190 preparation which
was not
visualized by silver staining (Fig.
2C) was recognized
by MAb 32.3B3.5
in Western blots and comigrated with an antigen
recognized in whole
T. foetus (Fig.
2D). The Tf190 preparation
was free of other
lower
Mr antigens recognized by MAb 32.3B3.5
(Fig.
2D).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Silver-stained 2 to 12% gradient SDS-PAGE gel of
solubilized oocysts before (lane 1, 1.5 × 106) and
after (lane 2, 10 µg) electrophoretic isolation of CPC205 (arrow).
Lane 3 was loaded with sample buffer to identify silver-stain
artifacts. (B) Western blot recognition of isolated CPC205 (lane 3, 10 µg) (arrow) and a 205-kDa comigrating antigen in solubilized oocysts
(1.5 × 106, lane 1) by MAb 4D3. Lane 2 (1.5 × 106 solubilized oocysts) and lane 4 (10 µg of CPC205)
were probed with isotype control MAb. Molecular mass standards
(Bio-Rad) are indicated on the left (myosin, 204 kDa;
-galactosidase, 121 kDa; BSA, 78 kDa). (C) Silver-stained SDS-7.5%
PAGE gel of solubilized T. foetus before (lane 1, 300 µg)
and after (lane 2, 10 µg) electrophoretic isolation of Tf190 (arrow).
Lane 3 was loaded with sample buffer, identifying a 70-kDa silver-stain
artifact. (D) Western blot recognition of isolated Tf190 (lane 3, 10 µg) (arrow) and comigrating antigen in solubilized organisms (300 µg, lane 1) by MAb 32.3B3.5. Lane 2 (300 µg of solubilized T. foetus) and lane 4 (10 µg of Tf190) were probed with isotype
control MAb. Molecular mass standards (Amersham) are indicated on the
left (myosin, 200 kDa; -galactosidase, 97.4 kDa; BSA, 69 kDa;
carbonic anhydrase, 46 kDa).
|
|
IEF-isolated CSL, but not CPC205 or Tf190, inhibited the CSP-like
reaction by 100% when coincubated with viable sporozoites
and MAb 3E2
(Table
1). This observation indicated
that the relevant
glycoprotein species mechanistically
involved in the CSP-like
reaction had been successfully isolated and
retained biologic
activity. Further, observations that CPC205 or Tf190
did not affect
the CSP-like reaction validated these
glycoproteins as appropriate
negative controls for binding
assays.
2-D electrophoretic analysis of whole C. parvum and
isolated CSL.
Because more than one CSL species or isoforms
differing in glycosylation state could exist and not have been
identified by silver-staining SDS-PAGE gels or Western blotting,
further characterization was of interest. In silver-stained 2-D
gels, approximately 15 (glyco)protein species (pI 3 to 10) in
whole C. parvum were identified in the 1,200- to 1,400-kDa
region known to contain CSL, a subset (pI 4 to 6.5) of which
was identified in IEF-isolated CSL (data not shown). In 2-D
Western blots of IEF-isolated CSL, four species having similar masses
(1,200 to 1,400 kDa) and pI values (~6) were corecognized by MAbs 3E2
and 4D10 (Fig. 3). However, MAb 3E2
recognized two additional species (~1,300 kDa, pI 4) (Fig. 3A) which
were not recognized by MAb 4D10 (Fig. 3B). No immunoreactivity was
observed in 2-D Western blots probed with isotype-matched control MAb.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 3.
2-D Western blots of isolated CSL (6 µg) demonstrating
antigen species migrating in the 1,200- to 1,400-kDa region (arrows)
which are recognized by MAb 3E2 (A) or MAb 4D10 (B). Note the
recognition of species 1 and 2 by 3E2 but not by 4D10. Molecular mass
standards (titin, 2,450 kDa; nebulin, 770 kDa) and pI values are
indicated on the left and bottom, respectively, of each panel.
|
|
MAb 3E2 inhibits sporozoite attachment and
invasion.
Caco-2 cells were selected for use in all in vitro
assays because of their human intestinal epithelial origin,
permissiveness to C. parvum infection and ability to support
complete development of all life cycle stages, and widespread use in
quantitating the activity of anticryptosporidial agents (21,
52). Caco-2 cell cultures inoculated with MAb 3E2-treated
sporozoites contained significantly (P < 0.0001) fewer
intracellular stages (217 ± 23) than cultures inoculated with
isotype control MAb-treated sporozoites (2,735 ± 210),
representing an ~92% reduction in sporozoite infectivity after
exposure to MAb 3E2. These findings and significance conclusions were
verified in a replicate experiment. The magnitude of sporozoite infectivity reduction observed in vitro, the ability of MAb 3E2 to
passively protect against C. parvum infection in vivo
(40), and the inability of certain other IgM or IgG MAbs
reactive with surface-exposed CSL epitopes distinct from that
recognized by 3E2 to neutralize infectivity (22, 40)
suggested that ligand-mediated attachment and/or invasion processes had
been inhibited by 3E2. To determine whether these potential mechanisms
of neutralization were operative, MAb 3E2-treated sporozoites were
inoculated onto Caco-2 monolayers and observed microscopically. MAb
3E2-treated sporozoites (Fig. 4), but not
isotype control mAb-treated sporozoites (Fig.
5), underwent the CSP-like reaction and
did not attach to Caco-2 cells during a 30-min observation period.
Consistent with previous observations (35, 36, 40), the
majority of sporozoites undergoing the CSP-like reaction remained
individualized; significant agglutination was not observed. These
findings were consistent in eight replicate experiments, indicating
that the initial attachment step of the infection process is inhibited
by MAb 3E2.

View larger version (139K):
[in this window]
[in a new window]
|
FIG. 4.
Time-lapse video photomicroscopic depiction of
sporozoite interactions with Caco-2 cells after incubation with MAb
3E2. Note that sporozoites (arrows) undergoing the CSP-like reaction
(arrowheads) after treatment with MAb 3E2 fail to attach and invade.
Bars, 7 µm. The time p.i. (in minutes) is indicated in each frame.
|
|

View larger version (154K):
[in this window]
[in a new window]
|
FIG. 5.
Time-lapse video photomicroscopic depiction of
sporozoite interactions with Caco-2 cells after incubation with isotype
control MAb. Note a sporozoite (arrow) probing the cell surface
(0:03.30), attaching (0:05.30), invading (0:07.00), and becoming
intracellular (0:08.30). Bars, 7 µm. The time p.i. (in minutes) is
indicated in each frame.
|
|
CSL specifically bound to Caco-2 cells inhibits sporozoite
attachment and invasion.
IEF-isolated CSL, but not CPC205 or
Tf190, bound to multifocal areas on the surface of viable Caco-2 cells
as determined by IFA with MAbs specific for each
glycoprotein (Fig. 6). These
observations demonstrated that CSL binding was specific. Further, after
incubation of Caco-2 cells with CSL, a dose-dependent decrease in
permissiveness to infection by sporozoites was observed. Specifically,
cultures incubated with CSL (0.5 to 2.0 µg/monolayer) prior to
sporozoite inoculation contained significantly fewer intracellular
stages than cultures incubated with CPC205 or Tf190 (0.5 to 2.0 µg
each/monolayer), or MEM, prior to inoculation (Fig.
7). Because cell viability exceeded 90%
after incubation with MEM (92% viable) or 2.0 µg each of CSL (93%
viable), CPC205 (91% viable), or Tf190 (91% viable), the observed
reduction in permissiveness in cultures incubated with CSL was specific
and not due to reduced cell viability caused by toxicity or other
nonspecific factors.

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 6.
Immunofluorescence photomicrographs of Caco-2 cell
monolayers incubated with IEF-isolated CSL (A), CPC205 (B), or Tf190
(C) and probed with MAbs 3E2, 4D3, or 32.3B3.5, respectively. Note the
specific binding of CSL (A), indicated by immunofluorescence reactivity
(arrows), and the absence of binding of control
glycoproteins CPC205 (B) and Tf190 (C). Bars, 7 µm.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7.
Dose-dependent reduction in Caco-2 cell permissiveness
to sporozoite infection by specifically bound CSL. Caco-2 cells were
incubated with MEM, or increasing amounts (0.25, 0.50, 1.0, or 2.0 µg) of IEF-isolated CSL ( ), CPC205 ( ), or Tf190 ( ) prior to
inoculation with sporozoites. The mean numbers of intracellular stages
in cells incubated with CSL were significantly lower than in those
incubated with CPC205 (P < 0.002) or Tf190
(P < 0.03) at 0.50 µg, CPC205 (P < 0.004) or Tf190 (P < 0.002) at 1.0 µg, and
CPC205 (P < 0.00002) or Tf190 (P < 0.00005) at 2.0 µg. The mean numbers of intracellular stages in
cultures incubated with MEM (6,866 ± 126), CPC205, or Tf190 were
not significantly different. Bars represent the standard deviation.
|
|
The kinetics of CSL binding to Caco-2 cells are consistent with a
sporozoite ligand function.
When Caco-2 cells were incubated with
increasing quantities of 125I-CSL, dose-dependent binding
was observed (Fig. 8A). Incubation of
cells with a fixed quantity of 125I-CSL and increasing
quantities of unlabeled CSL demonstrated self-displaceability. As the
amount of unlabelled CSL approached and then exceeded that of
125I-CSL (0.25 µg), bound counts per minute were
significantly reduced (Fig. 8B). These findings further supported the
specificity of CSL binding initially observed in binding experiments
evaluated by IFA. Specific radioactivity of 125I-CSL,
calculated from TCA precipitation values (0.48 µCi/µg of CSL),
represented an average specific radioactivity of all molecules comprising the preparation, assuming a 100% maximal binding capacity (44). The actual maximal binding capacity, determined to be 88% (Fig. 8C), was used to calculate a more accurate specific radioactivity (0.42 µCi/µg of CSL) for CSL binding saturability determination and Scatchard plot construction. When
125I-CSL (in micrograms) incubated with Caco-2 cells was
plotted against the corresponding B/F 125I-CSL values (in
counts per minute), decreasing B/F values and leveling of the resulting
curve with increasing 125I-CSL indicated that binding was
saturable (Fig. 8D). Concave upward curvature of the Scatchard plot
suggested that CSL bound to Caco-2 cells with negative cooperativity
(Fig. 8E) (24). KA and
KD were calculated at 3.65 × 108 M
1 and 2.74 × 10
9 M,
respectively (Fig. 8E) (28).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 8.
Kinetics of CSL binding to Caco-2 cells. (A)
Dose-dependent binding of CSL to Caco-2 cells, corrected for
nonspecific binding. (B) Self-displaceable binding of CSL to Caco-2
cells. The counts per minute of 125I-CSL bound in the
presence of 0.13 to 4 µg of unlabeled CSL compared to that of 0.06 µg of unlabelled CSL are significantly (P < 0.02)
lower. Bars represent the standard deviation (A and B). (C) Maximal
binding capacity of biologically active 125I-CSL as
determined from the ordinate of the y intercept for the best
fit line (dashed line). (D) Saturability of CSL binding to Caco-2
cells. Bars represent the standard deviation. (E) Scatchard plot
depicting the best-fit concave upward curvature line (dashed line).
|
|
 |
DISCUSSION |
We previously reported that CSL, an ~1,300-kDa apical complex
glycoprotein of sporozoites and merozoites, is the
molecular species mechanistically bound by neutralizing antibodies in
the CSP-like reaction of C. parvum (36, 40).
Because the infectivity of Plasmodium spp. sporozoites is
neutralized after the malarial CSP reaction (10, 30) and
region II-plus of the circumsporozoite protein bound in the reaction
contains a ligand for host cell receptors (8, 9, 16, 33), it
was of interest to further characterize the CSP-like reaction of
C. parvum and the function of CSL in the pathogenesis of
infection. In the present study we examined the role of CSL in
sporozoite attachment and invasion events. To perform the functional
studies reported herein, isolation of native CSL with preservation of
biological activity was required. An IEF method was used and allowed
recovery of adequate quantities of native CSL. IEF-isolated CSL was
capable of inhibiting the CSP-like reaction when incubated with MAb 3E2
and viable sporozoites, indicating retention of biological activity
after purification.
2-D electrophoretic analysis of whole C. parvum identified
approximately 15 1,200- to 1,400-kDa (glyco)protein species. Accurate quantitation was made difficult by the large number and the indiscreet silver staining pattern of the species identified, a feature which may
be observed in 2-D analysis of glycoproteins
(31). Nonetheless, this finding indicated that the
~1,300-kDa band recognized by 3E2 in single-dimension Western blots
(40) could have been comprised of more than one antigenic
species which differed in pI and Mr. Indeed,
preparative IEF isolated a subset of six 1,200- to 1,400-kDa species
specifically recognized by 3E2 in 2-D Western blots, at least one of
which was capable of inhibiting the CSP-like reaction. Previous studies
determined that the CSL epitope recognized by 3E2 is periodate
sensitive (40), indicating carbohydrate dependency and
possible sialic acid dependency (54). Therefore, the six species recognized by 3E2 in 2-D Western blots of CSL may reflect differences in glycosylation and/or sialysation states of a single glycoprotein, either of which could alter pI and
Mr (29, 31). Alternatively, the six
species recognized may be distinct glycoproteins. Of the
six species in IEF-isolated CSL recognized by 3E2, four were
corecognized by MAb 4D10. Importantly, the two species (~1,300 kDa,
pI 4) recognized by 3E2, but not by 4D10, may be mechanistically important in the CSP-like reaction because 4D10, unlike 3E2, does not
elicit this reaction.
The magnitude of reduction in intracellular stages in Caco-2 cells
inoculated with 3E2-treated sporozoites suggested that the attachment
and/or invasion processes had been inhibited. To better characterize
the mechanism of neutralization, sporozoite interactions with Caco-2
cells following 3E2 treatment were monitored by video microscopy,
allowing observation of events not readily examined in vivo.
3E2-treated sporozoites having undergone the CSP-like reaction did not
probe Caco-2 cells or attach, indicating that the initial step in
infection had been inhibited. However, IFA detection of small numbers
of intracellular stages in such cultures at 24 h p.i. indicates
that inhibition was not 100%. It is possible that subpopulations of
sporozoites which differ in the expression of CSL and ability to
undergo the CSP-like reaction exist and that those which do not undergo
the reaction remain infectious. Consistent with this possibility, 76 to
78% of the sporozoites in the present study, and a similar percentage
in previous studies (34), underwent the reaction after
incubation with 3E2. Alternatively, it is possible that CSL or other
functional sporozoite molecules contain additional ligands or that
C. parvum has redundant systems for mediating infection.
Failure of sporozoites to attach and invade after CSL binding by 3E2
first suggested that CSL might function as a sporozoite ligand. Several
subsequent lines of evidence from studies designed to investigate this
possibility indicate that CSL does indeed contain a sporozoite ligand
for Caco-2 cells. IEF-isolated CSL bound specifically to the surface of
viable Caco-2 cells and, once bound, decreased their permissiveness to
infection by sporozoites. These findings suggested CSL occupancy of one
or more host cell surface receptors specifically recognized during
infection. Additionally, in kinetics studies CSL bound to Caco-2 cells
with apparent high affinity in a dose-dependent, saturable, and
self-displaceable manner. Scatchard plot curvature suggested that
binding occurs with true or apparent negative cooperativity, resulting
in an increasing KD as Caco-2 receptor occupancy
by CSL increases (24). It is also possible that the concave
upward curvature of the Scatchard plot observed could be explained by
binding of more than one of the six CSL species identified in 2-D
Western blots. Taken together, these findings indicate that CSL meets
functional and biochemical definitions required for unequivocal
designation as a ligand-containing parasite glycoprotein.
Studies to determine which region(s) of CSL is involved in receptor
recognition are in progress.
While (glyco)protein ligands involved in attachment have been described
for other protozoans including Trypanosoma cruzi (20, 42), Entamoeba histolytica (45), and
Tritrichomonas foetus (5, 46), and apicomplexan
parasites closely related to C. parvum, including
Toxoplasma gondii (15, 27), Plasmodium
spp. (8, 16, 33), and Eimeria tenella
(51), there have been relatively few reports of such
molecules in C. parvum. TRAP-C1, a C. parvum
sporozoite apical protein having structural and sequence similarities
to the thrombospondin family of adhesion molecules and a predicted
molecular mass of 76 kDa has recently been reported (47).
Other investigators have described a C. parvum sporozoite surface protein having Gal-GalNAc lectin activity which may function in
adhesion (21, 53). In addition to CSL, it has been proposed that at least one other high-Mr C. parvum sporozoite apical glycoprotein, designated
GP900, functions as a sporozoite ligand (2). The presence of
multiple, distinct high-Mr sporozoite
glycoproteins in C. parvum (2, 26, 40,
41, 48, 49) is consistent with the 2-D electrophoresis findings
in the present study. The relationship, if any, between CSL
(40), GP900 (2), and other high-Mr C. parvum (glyco)proteins
(26, 41, 48) is presently unclear, although differences are
evident (35). For example, while both CSL and GP900 are
contained in sporozoite and merozoite micronemes, only CSL is also
contained in zoite dense granules (35, 40). In addition,
while both CSL and GP900 are also exposed on the surface of
zoites, only CSL has been reported to be translocated posteriorly along
the sporozoite pellicle by a cytoskeletal dependent, cytochalasin-d inhibitable process (35, 40); GP900 is
thought not to be bound to the sporozoite cytoskeleton (2).
Collectively, these studies (2, 21, 40, 47, 53) and the
present report suggest that C. parvum zoites may use more
than one ligand during infection, each having functional domains which
differ biochemically and in binding specificity. For example, it is
possible that proteins such as TRAP-C1, which contain peptide motifs
known to bind sulfated glycoconjugates, or sporozoite surface lectins
which have Gal-GalNAc binding specificity, may allow localization and
initial attachment to the host glycocalyx overlying intestinal mucosa.
After glycocalyx binding, zoite glycoproteins such as CSL
or GP900 may mediate specific attachment to enterocyte surface
membrane receptors and subsequent invasion. A functional role for both
carbohydrate-dependent and lectin ligands in C. parvum
infection is consistent with the apparent negative cooperativity
binding of CSL observed in the present study. Binding with negative
cooperativity may result from steric effects related to multivalent
receptors or ligands or to multiple receptor or ligand subpopulations
(24).
In this report we have demonstrated that CSL has properties which are
consistent with the expression of a sporozoite ligand for
intestinal epithelial cells. The defined functional role of CSL makes
it a rational target for passive immunization against cryptosporidiosis in immunocompromised or neonatal hosts and for active
immunization in immunocompetent hosts. Ongoing molecular studies on
CSL, as well as on the host cell receptor to which it binds, may
provide insight into additional modalities to structurally or
functionally disrupt ligand-receptor interactions involved in the
pathogenesis of infection.
 |
ACKNOWLEDGMENTS |
This work was supported by Public Health Service grant AI 30223 from the National Institutes of Health, Bethesda, Md., and U.S.
Department of Agriculture NRICGP grant 37204-0496. Rebecca C. Langer
was supported in part by funds from the Pathobiology Graduate Program
at the University of Arizona.
We thank Beth A. Auerbach-Dixon for excellent technical assistance,
Deborah A. Schaefer and Kathryn Huey Tubman for assistance with figure
preparation, Lynn A. Joens and J. Glenn Songer (University of Arizona)
for valuable discussions, John D. Dame (University of Florida,
Gainesville) for T. foetus, Donald E. Burgess (Montana State
University, Bozeman) for MAb 32.3B3.5, and Kuan Wang and Gustavo
Gutierrez (University of Texas, Austin) for the titin and nebulin
molecular weight standards.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Veterinary Science and Microbiology, Veterinary Science and
Microbiology Building, Rm. 202, University of Arizona, Tucson, AZ
85721. Phone: (520) 621-2355. Fax: (520) 621-6366. E-mail:
mriggs{at}u.arizona.edu.
Present address: Center for Tropical Diseases, University of Texas,
Galveston, TX 77555-0609.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Arrowood, M. J., and C. R. Sterling.
1987.
Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients.
J. Parasitol.
73:314-319[Medline].
|
| 2.
|
Barnes, D. A.,
A. Bonnin,
J. X. Huang,
L. Gousset,
J. Wu,
J. Gut,
P. Doyle,
J. F. Dubremetz,
H. Ward, and C. Petersen.
1998.
A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion.
Mol. Biochem. Parasitol.
96:93-110[Medline].
|
| 3.
|
Blagburn, B. L., and R. Soave.
1997.
Prophylaxis and chemotherapy, p. 111-123.
In
R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, Fla.
|
| 4.
|
Brown, W. C.,
T. F. McElwain,
I. Hotzel,
C. E. Suarez, and G. H. Palmer.
1998.
Helper T-cell epitopes encoded by the Babesia bigemina rap-1 gene family in the constant and variant domains are conserved among parasite strains.
Infect. Immun.
66:1561-1569[Abstract/Free Full Text].
|
| 5.
|
Burgess, D. E., and C. M. McDonald.
1992.
Analysis of adhesion and cytotoxicity of Tritrichomonas foetus to mammalian cells by use of monoclonal antibodies.
Infect. Immun.
60:4253-4259[Abstract/Free Full Text].
|
| 6.
|
Calvo, J. C.,
J. P. Radicella, and E. H. Charreau.
1983.
Measurement of specific radioactivities in labeled hormones by self-displacement analysis.
Biochem. J.
212:259-264[Medline].
|
| 7.
|
Carruthers, V. B., and L. D. Sibley.
1997.
Sequential protein secretion from three distinct organelles of Toxoplasma gondii accompanies invasion of human fibroblasts.
Eur. J. Cell Biol.
73:114-123[Medline].
|
| 8.
|
Cerami, C.,
U. Frevert,
P. Sinnis,
B. Takacs,
P. Clavijo,
M. J. Santos, and V. Nussenzweig.
1992.
The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites.
Cell
70:1021-1033[Medline].
|
| 9.
|
Cerami, C.,
U. Frevert,
P. Sinnis,
B. Takacs, and V. Nussenzweig.
1994.
Rapid clearance of malaria circumsporozoite protein (CS) by hepatocytes.
J. Exp. Med.
179:695-701[Abstract/Free Full Text].
|
| 10.
|
Cochrane, A. H.,
M. Aikawa,
M. Jeng, and R. S. Nussenzweig.
1976.
Antibody-induced ultrastructural changes of malarial sporozoites.
J. Immunol.
116:859-867[Abstract/Free Full Text].
|
| 11.
|
Diamond, L. S.
1987.
Lumen dwelling protozoa: Entamoeba, trichomonads, and Giardia, p. 65-109.
In
J. B. Jensen (ed.), In vitro cultivation of protozoan parasites. CRC Press, Boca Raton, Fla.
|
| 12.
|
Dubremetz, J. F.
1993.
Apical organelles (rhoptries, micronemes, dense granules) and host cell invasion by coccidia: what do we know now?
Proc. VIth Int. Coccidiosis Conf.
6:3-9.
|
| 13.
|
Duke, R. C., and J. J. Cohen.
1992.
Morphological and biochemical assays of apoptosis, p. 3.17.1-3.17.16.
In
J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
|
| 14.
|
Fayer, R.,
C. A. Speer, and J. P. Dubey.
1997.
The general biology of Cryptosporidium, p. 1-41.
In
R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, Fla.
|
| 15.
|
Fourmaux, M. N.,
A. Achbarou,
O. Mercereau-Puijalon,
C. Biderre,
I. Briche,
A. Loyens,
C. Odberg-Ferragut,
D. Camus, and J. F. Dubremetz.
1996.
The MIC1 microneme protein of Toxoplasma gondii contains a duplicated receptor-like domain and binds to host cell surface.
Mol. Biochem. Parasitol.
83:201-210[Medline].
|
| 16.
|
Frevert, U.,
P. Sinnis,
C. Cerami,
W. Shreffler,
B. Takacs, and V. Nussenzweig.
1993.
Malaria circumsporozoite protein binds to heparin sulfate proteoglycans associated with the surface membrane of hepatocytes.
J. Exp. Med.
177:1287-1298[Abstract/Free Full Text].
|
| 17.
|
Gillespie, P. G., and A. J. Hudspeth.
1991.
Chemiluminescence detection of proteins from single cells.
Proc. Natl. Acad. Sci. USA
88:2563-2567[Abstract/Free Full Text].
|
| 18.
|
Goding, J. W.
1996.
Analysis of antigens recognized by monoclonal antibodies, p. 234-326.
In
Monoclonal antibodies: principles and practice. Academic Press, San Diego, Calif.
|
| 19.
|
Heine, J.,
J. F. L. Pohlenz,
H. W. Moon, and G. N. Woode.
1984.
Enteric lesions and diarrhea in gnotobiotic calves monoinfected with Cryptosporidium species.
J. Infect. Dis.
150:768-775[Medline].
|
| 20.
|
Ivan-Ramirez, M.,
R. De Cassia-Ruiz,
J. Enrique-Araya,
J. Franco-Da Silveria, and N. Yoshida.
1993.
Involvement of the stage specific 82-kilodalton adhesion molecule of Trypanosoma cruzi metacyclic trypomastigotes in host cell invasion.
Infect. Immun.
61:3636-3641[Abstract/Free Full Text].
|
| 21.
|
Joe, A.,
R. Verdon,
S. Tzipori,
G. T. Keusch, and H. D. Ward.
1998.
Attachment of Cryptosporidium parvum sporozoites to human intestinal epithelial cells.
Infect. Immun.
66:3429-3432[Abstract/Free Full Text].
|
| 22.
|
Langer, R. C.
1998.
Ph.D. dissertation.
University of Arizona, Tucson.
|
| 23.
|
Langer, R. C., and M. W. Riggs.
1996.
Neutralizing monoclonal antibody protects against Cryptosporidium parvum infection by inhibiting sporozoite attachment and invasion.
In
Proceedings of the Fourth International Workshops on Opportunistic Protists, 13 June 1996, Tucson, Ariz. J. Eukaryot. Microbiol. 43:76S.
|
| 24.
|
Lauffenburger, D. A., and J. J. Linderman.
1993.
Cell surface receptor/ligand binding fundamentals, p. 9-72.
In
D. A. Lauffenburger, and J. J. Linderman (ed.), Receptors: models for binding, trafficking and signaling. Oxford Press, New York, N.Y.
|
| 25.
|
Lumb, R.,
K. Smith,
P. J. O'Donoghue, and J. A. Lanser.
1988.
Ultrastructure of the attachment of Cryptosporidium sporozoites to tissue culture cells.
Parasitol. Res.
74:531-536[Medline].
|
| 26.
|
McDonald, V.,
M. V. McCrossan, and F. Petry.
1995.
Localization of parasite antigens in Cryptosporidium parvum-infected epithelial cells using monoclonal antibodies.
Parasitology
110:259-268.
|
| 27.
|
Mineo, J. R., and L. H. Kasper.
1994.
Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30).
Exp. Parasitol.
79:11-20[Medline].
|
| 28.
|
Munson, P. J., and D. Rodbard.
1980.
LIGAND: a versatile computerized approach for characterization of ligand-binding systems.
Anal. Biochem.
107:220-239[Medline].
|
| 29.
|
Nag, B.,
S. Arimilli,
B. Koukis,
E. Rhodes,
V. Baichwal, and S. D. Sharma.
1994.
Intramolecular charge heterogeneity in purified major histocompatibility class II polypeptide and polypeptide chains.
J. Biol. Chem.
269:10061-10070[Abstract/Free Full Text].
|
| 30.
|
Nussenzweig, V., and R. S. Nussenzweig.
1989.
Rationale for the development of an engineered sporozoite malaria vaccine.
Adv. Immunol.
45:283-334[Medline].
|
| 31.
|
Otto, V. I.,
R. Fried,
F. Wiederkehr, and E. Hanseler.
1995.
Separation of the two most closely related isoenzymes of alkaline phosphatase by two-dimensional electrophoresis.
Electrophoresis
16:1284-1288[Medline].
|
| 32.
|
Perryman, L. E.,
D. P. Jasmer,
M. W. Riggs,
S. G. Bohnet,
T. C. McGuire, and M. J. Arrowood.
1996.
A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes.
Mol. Biochem. Parasitol.
80:137-147[Medline].
|
| 33.
|
Rich, K. A.,
F. W. George,
J. L. Law, and W. J. Martin.
1990.
Cell adhesive motif in region II of malarial circumsporozoite protein.
Science
249:1574-1577[Abstract/Free Full Text].
|
| 34.
| Riggs, M. W. Unpublished data.
|
| 35.
|
Riggs, M. W.
1997.
Immunology: host response and development of passive immunotherapy and vaccines, p. 129-162.
In
R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, Fla.
|
| 36.
|
Riggs, M. W.,
V. A. Cama,
H. L. Leary, Jr., and C. R. Sterling.
1994.
Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.
Infect. Immun.
62:1927-1939[Abstract/Free Full Text].
|
| 37.
|
Riggs, M. W.,
T. C. McGuire,
P. H. Mason, and L. E. Perryman.
1989.
Neutralization-sensitive epitopes are exposed on the surface of infectious Cryptosporidium parvum sporozoites.
J. Immunol.
143:1340-1345[Abstract].
|
| 38.
|
Riggs, M. W.,
M. R. McNeil,
L. E. Perryman,
A. L. Stone,
M. S. Scherman, and R. M. O'Connor.
1999.
Cryptosporidium parvum sporozoite pellicle antigen recognized by a neutralizing monoclonal antibody is a -mannosylated glycolipid.
Infect. Immun.
67:1317-1322[Abstract/Free Full Text].
|
| 39.
|
Riggs, M. W., and L. E. Perryman.
1987.
Infectivity and neutralization of Cryptosporidium parvum sporozoites.
Infect. Immun.
55:2081-2087[Abstract/Free Full Text].
|
| 40.
|
Riggs, M. W.,
A. L. Stone,
P. A. Yount,
R. C. Langer,
M. J. Arrowood, and D. L. Bentley.
1997.
Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites.
J. Immunol.
158:1787-1795[Abstract].
|
| 41.
|
Robert, B.,
H. Antoine,
F. Dreze,
P. Coppe, and A. Collard.
1994.
Characterization of a high molecular weight antigen of Cryptosporidium parvum micronemes possessing epitopes that are cross-reactive with all parasitic life cycle stages.
Vet. Res.
25:384-398[Medline].
|
| 42.
|
Ruiz, R. C.,
V. L. Rigoni,
J. Gonzalez, and N. Yoshida.
1993.
The 35/50 kDa surface antigen of Trypanosoma cruzi metacyclic trypomastigotes, an adhesion molecule involved in host cell invasion.
Parasite Immunol.
15:121-125[Medline].
|
| 43.
|
Sam-Yellowe, T. Y.
1996.
Rhoptry organelles of the apicomplexa: their role in host invasion and intracellular survival.
Parasitol. Today
12:308-316.
[Medline] |
| 44.
|
Schumacher, C., and V. von Tscharner.
1994.
Practical instructions for radioactively labeled ligand-receptor binding studies.
Anal. Biochem.
222:262-269[Medline].
|
| 45.
|
Seguin, R.,
B. J. Mann,
K. Keller, and K. Chadee.
1995.
Identification of the galactose-adherence lectin epitopes of Entamoeba histolytica that stimulate tumor necrosis factor-alpha production by macrophages.
Proc. Natl. Acad. Sci.
92:12175-12179[Abstract/Free Full Text].
|
| 46.
|
Shaia, C. I.,
J. Voyich,
S. J. Gillis,
B. N. Singh, and D. E. Burgess.
1998.
Purification and expression of the Tf190 adhesin in Tritrichomonas foetus.
Infect. Immun.
66:1100-1105[Abstract/Free Full Text].
|
| 47.
|
Spano, F.,
L. Putignani,
S. Naitza,
C. Puri,
S. Wright, and A. Crisanti.
1998.
Molecular cloning and expression analysis of a Cryptosporidium parvum gene encoding a new member of the thrombospondin family.
Mol. Biochem. Parasitol.
92:147-162[Medline].
|
| 48.
|
Tilley, M.,
M. T. Eggleston, and S. J. Upton.
1993.
Multiple oral inoculations with Cryptosporidium parvum as a means of immunization for production of monoclonal antibodies.
FEMS Microbiol. Lett.
113:235-240[Medline].
|
| 49.
|
Tilley, M., and S. J. Upton.
1997.
Biochemistry of Cryptosporidium, p. 163-180.
In
R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, Fla.
|
| 50.
|
Tomley, F. M.,
J. M. Bumstead,
K. J. Billington, and P. P. J. Dunn.
1996.
Molecular cloning and characterization of a novel acidic microneme protein (Et mic-2) from the apicomplexan protozoan parasite, Eimeria tenella.
Mol. Biochem. Parasitol.
79:195-206[Medline].
|
| 51.
|
Tomley, F. M.,
L. E. Clark,
U. Kawazoe,
R. Dijkema, and J. J. Kok.
1991.
Sequence of the gene encoding an immunodominant microneme protein of Eimeria tenella.
Mol. Biochem. Parasitol.
49:277-288[Medline].
|
| 52.
|
Upton, S. J.,
M. Tilley, and D. B. Brillhart.
1994.
Comparative development of Cryptosporidium parvum (Apicomplexa) in 11 continuous host cell lines.
FEMS Microbiol. Lett.
118:233-236[Medline].
|
| 53.
|
Ward, H. D.
1997.
Glycobiology of parasites: role of carbohydrate-binding proteins and their ligands in the host-parasite interaction, p. 399-413.
In
H.-J. Gabius, and S. Gabius (ed.), Glycosciences. Chapman & Hall, Weinheim, Germany.
|
| 54.
|
Woodward, M. P.,
W. W. Young, Jr., and R. A. Bloodgood.
1985.
Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation.
J. Immunol. Methods
78:143-153[Medline].
|
Infection and Immunity, October 1999, p. 5282-5291, Vol. 67, No. 10
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
O'Connor, R. M., Burns, P. B., Ha-Ngoc, T., Scarpato, K., Khan, W., Kang, G., Ward, H.
(2009). Polymorphic Mucin Antigens CpMuc4 and CpMuc5 Are Integral to Cryptosporidium parvum Infection In Vitro. Eukaryot Cell
8: 461-469
[Abstract]
[Full Text]
-
Riggs, M. W., Schaefer, D. A., Kapil, S. J., Barley-Maloney, L., Perryman, L. E.
(2002). Efficacy of Monoclonal Antibodies against Defined Antigens for Passive Immunotherapy of Chronic Gastrointestinal Cryptosporidiosis. Antimicrob. Agents Chemother.
46: 275-282
[Abstract]
[Full Text]
-
Langer, R. C., Li, F., Vinetz, J. M.
(2002). Identification of Novel Plasmodium gallinaceum Zygote- and Ookinete-Expressed Proteins as Targets for Blocking Malaria Transmission. Infect. Immun.
70: 102-106
[Abstract]
[Full Text]
-
Langer, R. C., Schaefer, D. A., Riggs, M. W.
(2001). Characterization of an Intestinal Epithelial Cell Receptor Recognized by the Cryptosporidium parvum Sporozoite Ligand CSL. Infect. Immun.
69: 1661-1670
[Abstract]
[Full Text]
-
Giacometti, A., Cirioni, O., Del Prete, M. S., Barchiesi, F., Scalise, G.
(2000). Short-Term Exposure to Membrane-Active Antibiotics Inhibits Cryptosporidium parvum Infection in Cell Culture. Antimicrob. Agents Chemother.
44: 3473-3475
[Abstract]
[Full Text]
-
Cevallos, A. M., Bhat, N., Verdon, R., Hamer, D. H., Stein, B., Tzipori, S., Pereira, M. E. A., Keusch, G. T., Ward, H. D.
(2000). Mediation of Cryptosporidium parvum Infection In Vitro by Mucin-Like Glycoproteins Defined by a Neutralizing Monoclonal Antibody. Infect. Immun.
68: 5167-5175
[Abstract]
[Full Text]
-
Cevallos, A. M., Zhang, X., Waldor, M. K., Jaison, S., Zhou, X., Tzipori, S., Neutra, M. R., Ward, H. D.
(2000). Molecular Cloning and Expression of a Gene Encoding Cryptosporidium parvum Glycoproteins gp40 and gp15. Infect. Immun.
68: 4108-4116
[Abstract]
[Full Text]
-
Schaefer, D. A., Auerbach-Dixon, B. A., Riggs, M. W.
(2000). Characterization and Formulation of Multiple Epitope-Specific Neutralizing Monoclonal Antibodies for Passive Immunization against Cryptosporidiosis. Infect. Immun.
68: 2608-2616
[Abstract]
[Full Text]